Associated tags: Patient, Physician, Medication, CNS, Health, GI, Greater Toronto Area, Infection, Conference, Pharmaceutical industry, Health Canada, Therapy, Meropenem, Vaborbactam, Priority review, Interest, Delafloxacin, Research, Pharmaceutical, Science, Biotechnology, Melinta Therapeutics
Locations: CV, CANADA
President & CEO, George Gafrey will be speaking at 11:00 AM ET on April 17th.
Key Points:
- President & CEO, George Gafrey will be speaking at 11:00 AM ET on April 17th.
- Interested parties can register to attend here .
- Members of the Xediton Pharmaceuticals Inc. management team will also be taking meetings throughout the day.
- To register for the 2024 Bloom Burton & Co. Healthcare Investor Conference, please follow this link .
Biotechnology,
Health,
Science,
Pharmaceutical,
Research,
Delafloxacin,
Priority review,
Partnership,
Infection,
Vaborbactam,
Patient,
Meropenem,
Therapy,
Health Canada,
Pharmaceutical industry,
Melinta Therapeutics Melinta Therapeutics, LLC (Melinta) and Xediton Pharmaceuticals Inc (Xediton) today announced they have entered into an exclusive commercialization and licensing agreement for BAXDELA® (delafloxacin), KIMYRSA® (oritavancin), ORBACTIV® (oritavancin) and VABOMERE® (meropenem and vaborbactam), four novel anti-infective products.
Key Points:
- Melinta Therapeutics, LLC (Melinta) and Xediton Pharmaceuticals Inc (Xediton) today announced they have entered into an exclusive commercialization and licensing agreement for BAXDELA® (delafloxacin), KIMYRSA® (oritavancin), ORBACTIV® (oritavancin) and VABOMERE® (meropenem and vaborbactam), four novel anti-infective products.
- Under the terms of the agreement, Xediton is responsible for the registration and commercialization of these products in Canada.
- “We are very pleased to partner with Melinta to bring these life-saving products to Canada.
- “We’re thrilled to enter into this partnership with Xediton, a recognized leader in specialty care pharmaceuticals in Canada.
